AstraZeneca Discontinues Lung Cancer Trial of Volrustomig
Pharmaceutical company AstraZeneca has halted its clinical trial evaluating volrustomig for the treatment of lung cancer.
PA
Priya Anand · Equities & Earnings Desk · 17 Aug 2026 · 1 min read
AstraZeneca has discontinued its clinical trial evaluating volrustomig as a treatment for lung cancer, according to a company announcement.
Volrustomig is an investigational immunotherapy candidate within the company's oncology pipeline. Further details regarding the reasons for the discontinuation were not immediately disclosed.
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →